product image

Saving and Improving
Patients' Lives

Our Story

Motivated by our purpose of saving and improving patients’ lives, Piramal Critical Care marked its entry in the field of inhalation anaesthetics in 2002 with the acquisition of ICI India Ltd. Since then, we have established our name as a global anaesthetics company with much of our growth developed through acquisitions of trusted and established manufacturers.

At Piramal Critical Care, we are on a constant endeavor to pinpoint the real needs of patients and providers to enable improvements in the anaesthesia community. With a rich history behind us and a bright future ahead, Piramal Critical Care dedicates our story to saving lives with critical care solutions.

Acquisition of pharmaceuticals business of ICI India Limited

Acquisition of Inhalation Anaesthesia business of Rhodia Organique Ltd., UK

Acquisition of brand Haemaccel from Pharmaselect, Germany

Acquisition of RxElite Inc., United States

Acquisition of Minrad Inc., United States

Acquisition of business unit AltaSelect S.r.l.

Acquisition of Injectable Anaesthetics business of BSV, India

Acquisition of Injectable Anaesthesia and Pain Management products from Janssen, Belgium

Acquisition of Intrathecal Spasticity and Pain Management drugs from Mallinckrodt, USA

Acquired YargesaTM (Miglustat) which is used for the treatment of Type I Gaucher & Niemann-Pick type C disease.

Acquired distribution license for injectable antibacterials such as Ampicillin and Sulbactam for Injection, USP, Cefepime for Injection, USP, Ceftriaxone for Injection, USP, Oxacillin for Injection, USP and Ampicillin for Injection, USP.

Started marketing Glycopyrrolate Injection, USP manufactured at our affiliate Pharma Solutions CMO facility in India.

PCC licensed Linezolid Injection from Georgetown Pharmacal.

Acquired distribution license for injectable antibacterial such as Piperacillin and Tazobactam for Injection, USP.

Acquired distribution license for Rocuronium Bromide Injection.

Acquired distribution license for Succinylcholine Chloride Injection, USP and Dexmedetomidine Injection, USP.

Acquired distribution license for Propofol-Lipuro emulsion for Injection or Infusion.

Values

The core values of Piramal Group and Piramal Critical Care are an integral piece of our guiding philosophy. Values are what connect and divide us as human beings. They determine how we engage with others, what we value, what we love, and what we deem worth fighting for. Therefore, living by our values is not just important but imperative.

Knowledge

Expertise – We strive for a deeper understanding of our domain.

Innovation – We aspire to do things creatively.

Action

Entrepreneurship – We are empowered to act decisively and create value.

Integrity – We are consistent in our thought, speech, and action.

Care

Trusteeship – We protect and enhance the interests of our customers, community, employees, partners, and shareholders.

Humility – We aspire to be the best, yet strive to be humble.

Impact

Performance – We strive to achieve market leadership in scale and profitability, wherever we compete.

Resilience – We aspire to build businesses that anticipate, adapt and endure for generations.